The genetic complexity of multiple myeloma is due in part to the accumulation of mutations, with primary and secondary events. One such secondary event is the development of a gene mutation that may result in overexpression of cyclin D1. The pathway involving cyclin D1 is intricately involved in cell cycle regulation from the G1 to S phase, and alterations may contribute to tumorigenesis. We present a case of cyclin D1-positive multiple myeloma with lymphoplasmacytic morphology and discuss potential diagnostic pitfalls and effects on prognosis.
The genetic complexity of multiple myeloma is due in part to the accumulation of mutations, with primary and secondary events. One such secondary event is the development of a gene mutation that may result in overexpression of cyclin D1. The pathway involving cyclin D1 is intricately involved in cell cycle regulation from the G1 to S phase, and alterations may contribute to tumorigenesis. We present a case of cyclin D1-positive multiple myeloma with lymphoplasmacytic morphology and discuss potential diagnostic pitfalls and effects on prognosis.
T he molecular pathway of tumorigenesis in multiple myeloma (MM) has been extensively studied but remains to be fully elucidated. A common model for clonal evolution of MM begins with a primary event, such as a chromosomal translocation, deletion, or a hyperdiploid state. Th e accumulation of secondary events occurs next and is believed to result in progression to MM. Secondary events include additional chromosomal translocations, deletions, and mutations involving specifi c genes such as KRAS, NRAS, MAF, and MAFB. One secondary event that can occur is the development of a mutation in cyclin D1. Up to 75% of plasma cell disorders have at least one mutation of retinoblastoma protein, p16INK4a, cyclin D1, or a related kinase in the G regulatory pathway commonly targeted in tumorigenesis (1). It has also been shown that overexpression of cyclin D1 in MM can present with diff erent plasma cell morphologies (2) . Cyclin D1 is involved in the regulation of the cell cycle, and inhibition of cyclin D1 function can reduce the proliferation of many different cell types (3) . Several mechanisms exist that may result in overexpression of cyclin D1, including the translocation t(11;14)(q13;q32) involving the immunoglobulin heavy chain promoter and cyclin D1 (4) . One recent study showed that overexpression of cyclin D1 in MM is an independent negative prognostic variable for overall survival (5) . Th e potential for shorter overall survival with varied plasma cell morphology leading to diagnostic pitfalls makes this unique entity one to be aware of in the fi eld of hematology.
CASE REPORT
A 51-year-old woman presented with anemia and chronic back pain. A workup revealed a compression fracture of L1 with an abnormal signal. Serum protein electrophoresis was negative at presentation, and the peripheral blood showed no abnormalities. A bone marrow biopsy was performed, and the aspirate smear showed few scattered plasma cells with numerous lymphoplasmacytic cells. Th e classic plasma cell morphology exhibiting an eccentric nucleus, perinuclear hof, and basophilic cytoplasm was seen in only 3% of cells on the diff erential count. Lymphoplasmacytic cells accounted for 25% of cells and were smaller with a markedly increased nuclear-to-cytoplasmic ratio as compared to the defi nitively identifi ed plasma cell population (Figure 1) . A diff erential diagnosis of lymphoplasmacytic lymphoma (LPL) versus lymphoid-appearing MM was entertained. Th e biopsy and clot preparation showed a 50% to 55% normocellular marrow with numerous lymphoplasmacytoid cells and only a few plasma cells.
Immunohistochemistry (IHC) was performed on the clot preparation, and CD138 showed 65% to 70% positive plasma cells. Cyclin D1 was diff usely positive in the plasma cells ( Figure 1e) . Th e plasma cells were CD56 positive, and a 25% to 30% subset of plasma cells was positive for CD20. In situ hybridization showed a >20-to-1 ratio of kappa to lambda. IHC confi rmed that the number of plasma cells was underestimated and convincingly showed that the lymphoplasmacytic cells were indeed plasma cells.
Flow cytometry found 21% variably sized plasma cells expressing CD20, CD56, CD138, and cytoplasmic kappa, but not CD45. No clonal B-cell population was identifi ed in the specimen. Because of the lymphoplasmacytic morphology, the specimen had been sent for MYD88 L265P mutation testing and was negative in our case. Chromosome analysis showed no abnormalities. Th e fi ndings were consistent with a cyclin D1-positive lymphoplasmacytic MM involving 65% to 70% of marrow cellularity.
The patient received four cycles of Revlimid-Velcadedexamethasone induction with partial response measured by be related to MM, but it has been determined to be a separate entity and is now classifi ed as LPL. Greater than 90% of bone marrow-based LPLs are positive for the MYD88 L265P mutation (6). Our case was negative for the MYD88 L265P mutation, and fl ow cytometry further helped rule out WMG by fi nding a clonal plasma cell population with no clonal B-cell population. In our case, it was diffi cult morphologically to distinguish a subset of lymphoplasmacytic cells from lymphocytes or plasma cells; in a setting of limited IHC, molecular, and cytogenetic testing, it is an important diagnostic consideration to include both LPL and MM in the diff erential diagnosis.
Th ere is confl icting data regarding the clinical signifi cance of cyclin D1 expression in MM. Cyclin D1 overexpression was found to identify a subset of MM patients who are more likely to have prolonged duration of remission and eventfree survival following autologous transplantation (7) . However, data from the same study found that there was not a statistically significant difference in overall survival between cyclin D1-positive and cyclin D1-negative groups (7) . While the aforementioned study related to transplantation, Moreau et al conducted a study to further investigate the prognostic value of specifi c chromosome rearrangements in MM patients treated with intensive chemotherapy. Th ey found that patients with chromosomal translocation t(11;14) displayed favorable outcomes in the form of longer overall survival as compared to patients with neither t(4;14) or t(11;14) (8). Cook et al also showed that IHC staining for cyclin D1 overexpression is associated with a longer overall survival time (9) . Yet another study revealed that cyclin D1 expression in MM treated with novel agents predicts a shorter overall survival as compared to cyclin D1-negative MM cases (5) . Th is study's participants consisted of a predominantly non-transplant-eligible population.
Th e wide variability in results for cyclin D1 overexpression suggests there are numerous unaccounted-for variables aff ecting disease progression relative to cyclin D1 levels. Th is large number of variables may contribute to the lack of consensus regarding cyclin D1 expression in MM. decreasing free light chains. Due to side eff ects, the regimen was altered, resulting in disease progression measured by rising free light chains. If a very good partial response is achieved, then the patient will be evaluated for autologous stem cell transplantation.
DISCUSSION
Th e diagnosis of cyclin D1-positive MM in our case was established by IHC, fl ow cytometry, and molecular testing. Th ese tests allowed us to rule out entities with lymphoplasmacytoid morphology such as Waldenström's macroglobulinemia (WMG), mantle cell lymphoma, and chronic lymphocytic leukemia. It is important to keep a high suspicion for cyclin D1-positive plasma cells in cases that show few classic plasma cells and numerous lymphoplasmacytic cells, which might lead to a misdiagnosis of lymphoma if additional testing is not performed.
Initially WMG was the primary consideration. WMG is a neoplasm of small B-cell lymphocytes, plasmacytoid lymphocytes, and plasma cells with bone marrow involvement and an IgM monoclonal gammopathy. WMG was once considered to 
